Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

Clinical trial NCT03357471 · COMPLETED

Trial details

NCT number: NCT03357471
Sponsor: UCB Biopharma S.P.R.L.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Moderate and Severe Active Rheumatoid Arthritis Active Psoriatic Arthritis Active Ankylosing Spondylitis Moderately to Severely Active Crohn's Disease

Start date: 2017-11-03
Primary completion: 2018-07-02
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.